An open-label study of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (RECAP)
Respiration Sep 15, 2017
Costabel U, et al. - The motivation behind this study was to obtain long-term safety data for pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) in RECAP. Researchers reported that RECAP provided long-term follow-up and safety data for pirfenidone that were consistent with the known profile, with no new safety signals seen.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
